Loading patent…
OwnerMahesh V. Patel, Nachiappan Chidambaram +7inventors
InventorsMahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara, Jonathan Ogle, Samuel Akapo, Joel Frank
Estimating the term…
The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.
A method of treating depression in a subject comprising orally administering to the subject an oral dosage form composition comprising or prepared from a neuroactive steroid (NAS) comprising 3α-OH-5α-pregnan-20-one in an amount of from about 10 mg to about 900 mg, wherein said administration provides at least one of the following values comprising:
A method of treating depression comprising:
A method of treating depression comprising:
A method of treating depression in a subject comprising orally administering to the subject a daily dose of from about 10 mg to about 900 mg of a composition comprising or prepared from a NAS comprising 3α-OH-5α-pregnan-20-one, wherein said administration provides a serum level Cmax of 3α-OH-5α-pregnan-20-one of greater than about 10 ng/ml, and wherein said administration comprises a plurality of doses of said composition administered at a frequency of at least four hours apart.
Dependencies are inferred from the claim text.